guardanthealth.com (GH): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Guardant Health - graphic logo of issuer GH

The EV/EBITDA valuation trend reflects the volatility of Guardant Health, Inc. (GH), which is burdened by debt and a lack of profitability amid its struggle for FDA approval. The business is currently transforming its strategy, shifting from recurrence monitoring to mass early screening. Meanwhile, the 0.00 metric indicates the maturity status of the asset, which strictly adheres to environmental regulations for biomaterial disposal.

GH (Guardant360) Company Value to EBITDA history from 11/23/2025 to 11/10/2026

Analytical breakdowns for Guardant Health, Inc.

- current price and projected stock value:
Stock Price Guardant360|GH - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Guardant Corp|GH - Total Company Value
- book value of equity indicators:
Accounting Value per Share Guardant Health|GH - Total Stockholders' Equity|Market Value to Book Value Ratio guardanthealth.com|GH - Company Total Asset Base
- business debt structure and liquidity details:
Total Debt to Capital Guardant Health, Inc.|GH - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Guardant Health|GH - Company Total Debt Obligations|Debts to Book Capitalization Guardant Corp|GH - Long-Term Indebtedness|Company Current Liabilities Guardant Health|Quick Ratio guardanthealth.com
- net income and valuation multiples indicators:
GH - Net Profit|Expected Profit Guardant Health, Inc.|GH - Company Value to Net Income|Forward P/E Multiple Guardant Health, Inc.|GH - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Guardant Corp|GH - Operating profit EBITDA|Earnings per share for the last twelve months Guardant Health|GH - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months guardanthealth.com|GH - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Guardant Health, Inc.
Comprehensive company analysis:Guardant360 GH
Product sample of Guardant Health

This indicator measures the total enterprise value including net debt relative to operating profit, allowing for an assessment of the real value of assets without the influence of tax distortions. By analyzing the business valuation level via the EV/EBITDA multiple on the GURU.Markets platform, an investor can see the financing efficiency of Guardant Health (GH) in developing liquid biopsy for cancer diagnostics and clinical research for biopharmaceutical companies.

Main competitors

EV/EBITDA Multiple CAI (Caris)|EV/EBITDA Multiple Veracyte Diagnostics VCYT|CELC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRAL: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MYGN (Myriad Genetics) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Castle Biosciences Inc (CSTL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Burning Rock Biotech Ltd.|VolitionRx Ltd (VNRX) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BDSX|Total Company Value to Operating Income Before Depreciation Ratio precipiodx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Check-Cap CHEK|Total Company Value to Operating Income Before Depreciation Ratio mainzbiomed.com (MYNZ)|OncoCyte Corp. - EV/EBITDA Multiple